We are live on ! Find out more
DAWN icon

Day One Biopharmaceuticals

Delisted

DAWN was delisted on the 22nd of April, 2026.

185 hedge funds and large institutions have $759M invested in Day One Biopharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 44 funds opening new positions, 74 increasing their positions, 43 reducing their positions, and 33 closing their positions.

New
Increased
Maintained
Reduced
Closed

72% more repeat investments, than reductions

Existing positions increased: 74 | Existing positions reduced: 43

33% more first-time investments, than exits

New positions opened: 44 | Existing positions closed: 33

10% more call options, than puts

Call options by funds: $7.37M | Put options by funds: $6.69M

6% more funds holding

Funds holding: 174 → 185 (+11)

4.39% less ownership

Funds ownership: 83.73% → 79.35% (-4.4%)

14% less capital inflows, than outflows

Capital inflows: $145M | Capital outflows: $168M

50% less funds holding in top 10

Funds holding in top 10: 4 → 2 (-2)

Holders
185
Holders Change
+11
Holders Change %
+6.32%
% of All Funds
2.22%
Holding in Top 10
2
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
44
Increased
74
Reduced
43
Closed
33
Calls
$7.37​M
Puts
$6.69​M
Net Calls
+$682​K
Net Calls Change
+$473​K

DAWN Hedge Fund Activity: Q4 2025 in Review

185 of the 8,317 institutional investors tracked by Wall St. Rank reported a position in Day One Biopharmaceuticals (DAWN) for Q4 2025, worth a combined $759M — up 26% from $605M a quarter earlier.

Buyers outnumbered sellers: 44 funds opened new DAWN positions and 33 closed out — a net gain of 11 holders — while 74 added to existing stakes and 43 trimmed.

The largest buyer was Vestal Point Capital, adding an estimated $21.1M. The largest seller was Fidelity Investments, cutting an estimated $36.6M.

  • 185 institutional investors held Day One Biopharmaceuticals (DAWN) as of Q4 2025, up from 174 in Q3 2025.
  • Funds reported $759M of Day One Biopharmaceuticals stock for Q4 2025, up 26% quarter-over-quarter.
  • 44 funds opened new Day One Biopharmaceuticals positions in Q4 2025 and 33 closed out, a net change of +11 holders.
  • The largest Day One Biopharmaceuticals buyer in Q4 2025 was Vestal Point Capital, an estimated $21.1M added.
  • The largest Day One Biopharmaceuticals seller in Q4 2025 was Fidelity Investments, an estimated $36.6M sold.

Based on aggregated 13F filings for Q4 2025.